50 results
Page 2 of 3
6-K
EX-99.3
muta1x3rm8tq
5 Aug 22
Current report (foreign)
6:07am
6-K
EX-99.1
hn9c4ixgiqpt11b6
26 Jul 22
InflaRx Announces Plans to Apply for Emergency Use Authorization from the US FDA for Vilobelimab for Treatment of Critically Ill COVID-19 Patients
8:35am
6-K
EX-99.3
y2namiy9edt1 e4bqxjg
12 May 22
Current report (foreign)
8:30am
6-K
EX-99.1
5jgsah4x2ne19t
7 Apr 22
Current report (foreign)
4:01pm
6-K
EX-99.1
t4tuz eo5g
31 Mar 22
InflaRx Announces Encouraging Phase III Topline Results from PANAMO Trial of Vilobelimab in Severe COVID-19 Patients
4:51pm
6-K
EX-5.2
jj7ywprt6nl4fhc g8wg
1 Mar 21
Current report (foreign)
12:00am
6-K
EX-99.1
0u3ryof06cne vs7g467
1 Mar 21
Current report (foreign)
12:00am
424B5
jkyp3opc46u4zc6m
26 Feb 21
Prospectus supplement for primary offering
5:10pm
424B5
821nbaauq7 g14g
24 Feb 21
Prospectus supplement for primary offering
5:16pm
6-K
zqdwrfrs7f5yts
24 Feb 21
Current report (foreign)
4:16pm
424B5
bqx44ddducqpawj1
20 Jul 20
Prospectus supplement for primary offering
9:21am
6-K
EX-99.1
vgiuj6ahx ys
20 Jul 20
from 6-K
9:02am
F-3
EX-5.2
fspngf3znzhe87xkpc4e
8 Jul 20
Shelf registration (foreign)
12:00am
F-3
n1azo
8 Jul 20
Shelf registration (foreign)
12:00am
6-K
1u89ef72kiezpt9gy
2 Mar 20
Current report (foreign)
4:05pm